GregoryJRielyMDPhD

Thoracic Cancer

Attending Physician Thoracic Oncology Service, Department of Medicine, Memorial Hospital Member Memorial Sloan Kettering Cancer Center

Request Appointment

Overview of Dr. Riely

Dr. Gregory Riely is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 16 years. Dr. Riely accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 89 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(313) 486-5290

Fax+1 646-227-7276

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2003
Case Western Reserve University School of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2003 - 2026
NJ State Medical License 2022 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Salirasib to Treat Non-Small Cell Lung Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 2
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib Start of enrollment: 2006 Jun 01
Completed
Phase 2
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors Start of enrollment: 2007 Dec 01
Completed
Phase 1
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib Start of enrollment: 2008 Jul 01
Completed
Phase 1, Phase 2
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Start of enrollment: 2009 Dec 01
Active, not recruiting
Phase 2
Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus Start of enrollment: 2011 Feb 08
Completed
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers Start of enrollment: 2012 Apr 16
Completed
Phase 1
Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D Start of enrollment: 2013 Apr 11
Completed
Phase 2
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib Start of enrollment: 2014 Jun 01
Withdrawn
Phase 2
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies Start of enrollment: 2014 Jun 06
Completed
Phase 1, Phase 2
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer Start of enrollment: 2018 Oct 31
Active, not recruiting
Phase 1
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Start of enrollment: 2018 Oct 09
Completed
Phase 1, Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Start of enrollment: 2020 May 28
Recruiting
Phase 2
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2019 Oct 31
Recruiting
Phase 1, Phase 2
Roles: Sub-Investigator
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer Start of enrollment: 2023 Aug 17
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

5 citations
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant,-Mutant, Metastatic Nonsquamous Non-Small ...
James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, Yun Fan, Filippo de Marinis
Journal of Clinical Oncology. 2024-12-01
Annotated test-retest dataset of lung cancer CT scan images reconstructed at multiple imaging parameters.
Binsheng Zhao, Laurent Dercle, Hao Yang, Gregory J Riely, Mark G Kris
Scientific Data. 2024-11-20
1 citations
Automated real-world data integration improves cancer outcome prediction.
Justin Jee, Christopher Fong, Karl Pichotta, Thinh Ngoc Tran, Anisha Luthra
Nature. 2024-11-06

Journal Articles

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers
Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers
G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology
YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics
Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.
2019 ASCO Annual Meeting - 6/1/2019
American Society for Radiation Oncology(ASTRO): 20th Chicago Multidisciplinary Symposium inThoracic Oncology
American Society for Radiation Oncology, Chicago, Illinois - 9/6/2012
Treating Stage I to III Non-Small-Cell Lung Cancer With Limited Evidence
2013 International Conference, Philadelphia, Pennsylvania, USA
Treating Stage I to III Non-Small-Cell Lung Cancer With Limited Evidence
American Thoracic Society, 2013 International Conference, Philadelphia, Pennsylvania, USA
Join now to see all

Press Mentions

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerSeptember 14th, 2024
Second Drug Targeting KRASG12C Shows Benefit in Mutated Non-Small-Cell Lung CancerMarch 25th, 2021
Lung Cancer | Current Concepts and Recent Advances in Oncology Part 1: Lung CancerDecember 30th, 2020
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPO
Humana ChoiceCare Network PPO
Kaiser Permanente
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment